abstract |
Humanized and variant anti-VEGF antibodies that bind human vascular endothelial growth factor with a Kd value of no more than 1x10-8 are provided. The anti-VEGF antibodies inhibit VEGF-induced proliferation of endothelial cells in vitro, and inhibit tumour growth in vivo. The antibodies may be used in the treatment of cancer and retinal disorders. |